Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.
The chart below shows how we grade Autonomix Medical (AMIX) across the board compared to its closest peers.
Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.
3.76
Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.
See how Autonomix Medical compares to its peers in these key performance metrics from Benzinga Rankings.
The two main factors that we consider when analyzing past performance is overall return and volatility
Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.
This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.
Autonomix Medical (AMIX) sharpe ratio over the past 5 years is -0.0353 which is considered to be below average compared to the peer average of -0.0050